The Adiposity-Inflammation Axis in T2D: Implications for Heart and Kidney

Nearly 50% of T2D patients have complications at diagnosis, often alongside hypertension, overweight, kidney damage, and high cardiovascular risk⁴. Compounding this burden, cardiovascular disease among Indian people living with diabetes manifests one to two decades earlier than in Western populations, carrying a disproportionately higher mortality rate⁵.

T2D & Obesity- Association with Augmented Cardiometabolic & Renal Risk

T2DM patients carry a 2–5 times higher risk of macrovascular disease, with 60–70% clinically obese and 70–80% burdened by hypertension or elevated LDL-C. Obesity directly amplifies this risk — high BMI increases coronary heart disease risk by up to 28%, even with apparently controlled glycemia and blood pressure. A bidirectional DKD–CVD relationship further entraps obese T2DM patients in a vicious cardiorenal cycle, where each condition accelerates the progression of the other⁶.

Adiposity-driven inflammation on Heart & Kidney in T2D- Pathophysiological Interactions

In obese T2D patients, visceral fat releases TNF-α, IL-6, and NF-κB-activating cytokines that impair endothelial NO production, promoting renal microvascular injury and atherosclerosis. Perirenal fat directly causes renal arterial dysfunction via oxidative stress and lipotoxicity. Excess adiposity exceeds storage capacity, increasing ectopic lipid flux to liver and muscle — driving insulin resistance, dyslipidemia, and cardiovascular risk. Furthermore, RAAS activation, TGF-β-mediated fibrosis, and microvascular rarefaction collectively accelerate CKD and heart failure progression. Adipose hypoxia and reduced adiponectin further amplify both cardiorenal injuries simultaneously^7,8. ,

Figure: Obesity, T2D & Cardio-Renal Risk Interactions.

Recreated from Méndez Fernández AB, et al. Front Cardiovasc Med. 2023;10:1185707. Abbreviations: HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular

Impact of Weight Reduction on Cardio-Metabolic Risk Factors & CV Event Outcomes in T2D:

A retrospective cohort study analyzed electronic health records from 63,567 adult patients over a mean follow-up of 6.6 years. Patients were classified as Obesity Maintainers (OM; 67%), Weight Loss Rebounders (WLR; 19%), and Weight Loss Maintainers (WLM; 14%), those who lost >5% body weight and sustained ≥80% of that loss. WLM showed the greatest cardiometabolic benefit (Figure 1). Benefits were incremental: patients sustaining >15% weight loss had a 54% lower T2DM risk, with significantly lower HbA1c (−0.23% vs OM; p <0.0001) and systolic BP (−2.81 mmHg vs OM; p <0.0001). The study concluded that both the magnitude and sustainability of weight loss are directly associated with delayed onset and improved outcomes of cardiometabolic disease⁹.

Weight Reduction – Important Therapeutic Goal to Improve CV & Metabolic Outcomes in T2D

The IDF (2025) guidelines recommend weight loss as a key therapeutic goal in T2DM management. Among incretin-based therapies, injectable semaglutide demonstrated significant weight reduction and improved HbA1c, CVD, renal, and heart failure outcomes in overweight/obese patients with T2DM¹⁰.

The ADA Standards of Care 2026 recommend weight management as a primary treatment goal in T2DM. Injectable semaglutide achieved 6.2% greater weight loss and 1.2% A1C reduction versus placebo, with added cardiovascular and heart failure benefits¹¹.

An Era of Practice Transformation in Cardio-Metabolic Care in Indian T2D: GLP-RA Access on the Horizon

With expanding GLP-1 RA access on the horizon across Indian clinical settings, a paradigm shift is underway in T2D care. Injectable semaglutide delivers compelling cardiometabolic protection: a 26% reduction in 3P-MACE (SUSTAIN 6), 24% lower risk of major kidney disease events (FLOW trial; HR 0.76), and meaningful reductions in albuminuria — directly targeting the adiposity-driven cardiorenal cascade^12,13. ,

Final Words

✔ India's T2DM burden is compounded by early-onset CVD, with 60–70% of patients clinically obese and nearly 50% presenting with complications at diagnosis, indicating the urgency of adiposity-targeted organ protection interventions to improve outcomes.

✔ Visceral fat-driven inflammation triggers a self-perpetuating cardiorenal cascade via endothelial dysfunction, RAAS activation, and TGF-β-mediated fibrosis, making the adiposity–inflammation axis a central therapeutic target in T2D.

✔ Injectable semaglutide-mediated weight reduction translates directly into cardiovascular protection, delivering a 26% reduction in 3P-MACE (SUSTAIN 6) alongside 6.2% greater weight loss versus placebo, reinforcing sustained weight reduction as a disease-modifying goal in T2D.

✔ As GLP-1 RA access will expand across Indian clinical settings, injectable semaglutide — supported by AACE 2025 and ADA 2026 recommendations will offer transformative cardiorenal protection heralding a new era in T2D care.

Abbreviations: ADA, American Diabetes Association; AACE, American Association of Clinical Endocrinology; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; DKD, diabetic kidney disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HR, hazard ratio; IDF, International Diabetes Federation; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events; NF-κB, nuclear factor kappa B; NO, nitric oxide; OM, obesity maintainers; RAAS, renin-angiotensin-aldosterone system; SC, subcutaneous; T2D/T2DM, type 2 diabetes mellitus; TGF-β, transforming growth factor beta; TNF-α, tumour necrosis factor alpha; WLM, weight loss maintainers; WLR, weight loss rebounders; 3P-MACE, three-point major adverse cardiovascular events